$MDT

Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off

Medtronic (MDT) set a final exchange ratio of 4.5939 shares of MiniMed (MMED) common stock for each Medtronic ordinary share in its split-off offer. The exchange offer, managed by Goldman Sachs and BofA Securities, expires October 9, 2026, unless extended. Medtronic may accept up to 55,032,401 shares if oversubscribed.

Original reporting
Published Oct 7, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 11:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$MDT
Neutral
high confidence
Mentioned
$MDT · $MMED
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$MDTNeutralHigh
01

Why it matters

The fixed ratio provides clarity for shareholders, creating immediate trading opportunities around the tender deadline.

02

Market read

The announcement is a primary corporate action for two large‑cap stocks, offering a short‑term catalyst for traders.

03

What to watch

Potential tax implications for shareholders and the execution risk of the proration process could affect the actual share exchange outcome.

Relevance 8/10Novelty 8/10Timing: pre‑market today, before the Oct 9 tender deadline

Background

Medtronic announced a split‑off of its MiniMed insulin‑pump business, offering a fixed exchange ratio of 4.5939 MiniMed shares for each Medtronic share.

Company-level read

Ticker impact

$MDTNeutralHigh confidence
Context

Medtronic disclosed the final exchange ratio for its split‑off of MiniMed, setting the terms of the share‑for‑share offer.

Expected impact

potential downside for MDT as tendering proceeds; upside for MMED as the ratio is locked in

Evidence & confidence

The announcement defines the conversion terms and deadline, giving traders a clear catalyst to act before the Oct 9 cutoff.

$MMEDBullishHigh confidence
Context

MiniMed received the final exchange ratio for the split‑off, establishing how many MiniMed shares each Medtronic share will convert into.

Expected impact

upward pressure on MMED as investors price in the fixed conversion rate

Evidence & confidence

The fixed 4.5939‑to‑1 ratio provides certainty, prompting demand for the newly independent MiniMed shares.

Market effects

The split‑off may affect the broader medical‑device sector as investors reassess exposure to Medtronic's core businesses versus the standalone insulin‑pump business.

Limited to U.S. and European markets where MDT and MMED trade.

Moderate, given Medtronic's size and the strategic significance of the MiniMed separation.

Counterpoint

Some investors may view the split‑off as a dilution risk for MDT shareholders if the MiniMed business underperforms post‑separation.

Key entities

  • Medtronic plc

    Global medical‑device manufacturer (NYSE: MDT).

  • MiniMed Group, Inc.

    Insulin‑pump business being spun off (Nasdaq: MMED).

Related articles

$MDTMed

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Medtronic's MiniMed Vivera algorithm showed promise in managing type 1 diabetes without meal announcements, with participants maintaining glycemic targets. The twiist AID system from Sequel Med Tech received FDA clearance for type 2 diabetes, showing improved HbA1c and time-in-range in trials. Both systems aim to reduce user input in automated insulin delivery.

$MDTMed

Medtronic reports real-world findings for cardiac ablation systems

Medtronic reported positive real-world registry findings for its cardiac ablation technologies, presented at the APHRS 2026 meeting. The PulseSelect PFA system showed a 100% success rate in AFib patients with a 0.09% complication rate. The Affera system with Sphere-9 catheter had a 1.1% major complication rate in AFib patients and an 87% success rate in VT patients. Medtronic's vice-president expressed confidence in the safety and performance of these technologies.

$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

MedAI 8/10

Medtronic’s next-gen pacemaker portfolio secures CE mark

Medtronic's Vitalis portfolio of next-gen pacemakers, designed for conduction system pacing (CSP) therapy, received a CE mark. The five pacemakers include advanced features like AdaptivCSP for heart synchrony. Medtronic claims this offers a more physiologic pacing option. GlobalData reports Medtronic leads the US pacemaker market with 58.7% share in 2025, with the global market growing at a 4.9% CAGR.

$MDTHigh

Medtronic nets CE Mark for Vitalis family of conduction system pacemakers

Medtronic (MDT) received CE Mark approval for its Vitalis family of pacemakers, designed for conduction system pacing. The portfolio includes five devices targeting various patient needs, such as the ReSyncra CSP for cardiac resynchronization therapy. The devices aim to improve heart synchronization by targeting conductive tissues, offering personalized therapy and remote monitoring. According to Medtronic, the portfolio builds on its history in cardiac electrophysiology therapies.